InventisBio is building up a pipeline of small molecule drug candidates targeting oncology and metabolic therapeutic areas. Currently four compounds, BPI-D0316, D-0502, D-0120, and D-1553 have been developed into clinical studies for the treatment of non-small cell lung cancer (NSCLC), breast cancer, CRC, and gout.


*Co-development with Betta Pharma


  • InventisBio actively pursues diversified collaborations with other companies, research institutes and universities to develop innovative drug products. Through scientific collaborations, joint clinical trials, and partnership in manufacturing and sales, we strive to accelerate commercialization of novel therapies in China and the rest of the world to address unmet medical needs, and to create a win-win situation. Currently, InventisBio is collaborating with other companies in the fields of oncology and immuno-oncology to develop clinical projects.

© 2019-2021 InventisBio Co., Ltd.